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While it is known that the arachidonic acid metabolite
20-hydroxyeicosatetraenoic acid (20-HETE) contributes to
ischemic injury in the heart and brain, its role in kidney
injury is unclear. Here we determined the effects on
ischemia-reperfusion injury of the 20-HETE analogues,
20-hydroxyeicosa-5(Z), 14(Z)-dienoic acid (5,14-20-HEDE),
and N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine
(5,14-20-HEDGE), and of the inhibitor of 20-HETE synthesis
N-hydroxy-N-(4-butyl-2 methylphenyl) formamidine
(HET0016). Using Sprague-Dawley rats we found that while
treatment with the inhibitor exacerbated renal injury,
infusion of both 5,14-20-HEDE and 5,14-20-HEDGE
significantly attenuated injury when compared to vehicle
or inhibitor-treated rats. Medullary blood flow, measured
by laser-Doppler flowmetry, decreased to half of the
baseline one hour after reperfusion in the control rats, but
5,14-20-HEDGE completely prevented this. Treatment of
control animals with 5,14-20-HEDGE increased urine output
and sodium excretion without altering their mean arterial
pressure or glomerular filtration rate. Our results suggest
that 20-HETE analogues protect the kidney from
ischemia-reperfusion injury by inhibiting renal tubular
sodium transport and preventing the post-ischemic fall in
medullary blood flow. Analogues of 20-HETE may be useful
in the treatment of acute ischemic kidney injury.
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Ischemic acute kidney injury contributes to kidney dysfunc-
tion and patient morbidity in a variety of clinical settings
ranging from cardiovascular surgery to kidney transplanta-
tion.1 The renal injury following ischemia-reperfusion (I/R)
results from multiple factors involving both changes in renal
hemodynamics and injury to tubular epithelial cells.2 Acute
ischemia leads to adenosine triphosphate depletion and
initiates tubular cell injury. Following reperfusion, this injury
is exacerbated by leukocyte activation, cytokine production,
and an increase in reactive oxygen species.3 This may result
in renal tubular epithelial cell necrosis or activation of
apoptotic pathways in susceptible nephron segments.4
Alterations in renal hemodynamics following I/R have been
well characterized and include loss of normal vascular
reactivity and renal autoregulation, endothelial cell injury,
red blood cell trapping, and impaired medullary blood
flow (MBF).2,5–7 Compromised MBF in particular is thought
to further ischemic injury because oxygen supply is
inadequate to support the ongoing metabolic demands of
tubular transport.2
Ischemic insults may activate membrane bound phospho-
lipase A2 which stimulates the release of arachidonic acid
(AA) from membrane phospholipids.8 Depending on the cell
type, AA can then be metabolized into prostaglandins,
leukotrienes, and 5-,12-, and 15-HETE by cyclooxygenases
and lipoxygenases.9 The cytochrome P450 (CYP) system
provides an additional pathway for AA metabolism. 20-
Hydroxyeicosatetraenoic acid (20-HETE) is a product of CYP
o-hydroxylase-mediated metabolism of AA and is produced
in the kidney where it serves as an important regulator of
vascular tone, renal blood flow (RBF), renal tubular sodium
transport, and activates a number of intracellular signal
transduction pathways involved in cell growth and survi-
val.9,10 Recent studies have found that 20-HETE contributes
to ischemic injury in the heart and brain and that inhibitors
of the synthesis of 20-HETE reduce infarct size after
reperfusion injury in both of these organs.10–13
Little is known about the function of 20-HETE in renal
I/R injury. This is partially due to the lack of specific
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inhibitors of this pathway or molecular tools that can inhibit
the CYP4A and -4F isoforms that produce 20-HETE in
the kidney. At present, seven isoforms are known to produce
renal 20-HETE which limits the utility of knockout or siRNA
techniques that target a single isoform.9 However, the recent
development of synthetic 20-HETE analogues has stimulated
investigation into the function of 20-HETE in various
disease models.14,15 This study examined the effects of stable
20-HETE analogues on the severity of experimental renal
I/R injury in rats and explored their effect on renal
sodium reabsorption and postischemic changes in renal
hemodynamics.
RESULTS
Plasma concentrations of 20-HETE analogues following
subcutaneous injection
Plasma concentrations of 20-hydroxyeicosa-5(Z),14(Z)-dienoic
acid (5,14-20-HEDE) and N-(20-hydroxyeicosa-5(Z),14(Z)-
dienoyl)glycine (5,14-20-HEDGE) at 1, 4, 8, and 24 h after
injection are presented in Figure 1. Peak blood levels were
366.9±31.46 and 253.6±39.87 ng/ml for 5,14-20-HEDE and
5,14-20-HEDGE, respectively (P¼ 0.11). The half-lives of the
two analogues were similar and averaged approximately 4 h.
Effect of 20-HETE on renal I/R injury
In vehicle-treated control rats, plasma creatinine increased
from 0.5±0.05 to 2.8±0.3 mg/100 ml 24 h after ischemia
(Figure 2). Blockade of the formation of 20-HETE by
HET0016 exacerbated renal dysfunction as indicated by a
significant increase in plasma creatinine levels. Pretreatment
of the rats with the 20-HETE analogue, 5,14-20-HEDE
(10 mg/kg), reduced plasma creatinine by approximately
50%. 5,14-20-HEDGE appears to be more efficacious in that
a 10-fold lower dose (1 mg/kg) was able to almost completely
prevent the rise in plasma creatinine 24 h following renal
I/R injury. Furthermore, 5,14-20-HEDGE also mitigated
renal I/R injury when administered after reperfusion (5,14-
20-HEDGE group B).
Effects of 20-HETE analogues on renal tubular injury and
apoptosis following I/R
The histological appearance of tubular injury at the
corticomedullary junction is presented in Figure 3. Fluores-
cence microscopy of the hematoxylin and eosin (H&E)-
stained sections demonstrates distinct autofluorescence of
necrotic tubules and tubular casts (Figures 3a and b). Diffuse
tubular cell denudation, tubular cell necrosis, intratubular
debris, and tubular casts were present in vehicle and
HET0016-treated animals (Figure 3c). Administration of a
20-HETE analogue (5,14-20-HEDE or 5,14-20-HEDGE)
resulted in less severe renal injury with only focal tubular
necrosis or exfoliation of tubular cells (Figure 3c). The degree
of renal injury was further quantified by morphometric
analysis of autofluorescence in H&E-stained sections. Ad-
ministration of a 20-HETE analogue (5,14-20-HEDE or 5,14-
20-HEDGE) resulted in a marked reduction in the area
occupied by necrotic tubular epithelium or cast material
compared to vehicle- or HET0016-treated animals (Figure
3d). Furthermore, pretreatment with a 20-HETE analogue
markedly reduced the number of apoptotic cells identified by
terminal transferase dUTP nick-end labeling (TUNEL)
staining compared to vehicle-treated controls (Figure 4).
Effect of the 20-HETE analogue, 5,14-20-HEDGE, on renal
hemodynamics
Baseline cortical blood flow (CBF) and MBF were similar in
the rats that received vehicle or 5,14-20-HEDGE. 5,14-20-
HEDGE did not have a significant effect on CBF or MBF
before the induction of renal ischemia. As expected, CBF and
MBF fell by greater than 90% in both groups during the
ischemic period and recovered after reperfusion. In vehicle-
treated rats, MBF decreased to approximately 50% of baseline
by 60 min following reperfusion and remained at that level
throughout the remainder of the experiment (Figure 5b),
which was equivalent to 3 h after reperfusion. In contrast,
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Figure 1 | Chemical structures of 20-HETE analogues and
plasma concentrations after subcutaneous injection.
(a) Chemical structures of 20-HETE and the 20-HETE analogues
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid (5,14-20-HEDE) and
N-(20-hydroxyeicosa-5(Z),14(Z)-dienoyl)glycine (5,14-20-HEDGE).
(b) Time course of plasma levels of 20-HETE analogues following
10 mg/kg s.c. injection of 5,14-20-HEDE or 5,14-20-HEDGE in rats.
*Po 0.001 vs the corresponding value in the 5,14-20-HEDGE-
treated group.
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Figure 2 | Effect of 20-HETE analogues on renal dysfunction
24 h after renal I/R injury. Rats were pretreated with vehicle;
HET0016 (5 mg/kg s.c.), an inhibitor of the synthesis of 20-HETE; or
the 20-HETE analogues 5,14-20-HEDE (10 mg/kg s.c.) or 5,14-20-
HEDGE group A (1 mg/kg s.c.). 5,14-20-HEDGE group B received
5,14-20-HEDGE (1 mg/kg s.c.) 1 min after reperfusion. The bilateral
nephrectomy group (Bil-Nx) served as an absolute renal failure
control. Mean values±s.e. are presented. *Po 0.05 vs vehicle
control group. wPo0.05 vs HET0016 group.
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pretreatment of the rats with 5,14-20-HEDGE prevented the
postischemic fall in MBF (Figure 5b). 5,14-20-HEDGE had
no effect on postischemic CBF (Figure 5a) or mean arterial
pressure (MAP) (Figure 5c) when compared to vehicle-
treated rats.
In nonischemic rats, administration of 5,14-20-HEDGE
did not significantly alter MAP, RBF, glomerular filtration
rate (GFR), or urine potassium excretion when compared to
control values (Figures 6 and 7). However, administration of
5,14-20-HEDGE was associated with significant increases in
urine flow and urine sodium excretion compared to control
values (Figure 7).
DISCUSSION
This study examined the function of 20-HETE in renal I/R
injury. The results indicate that blockade of the formation of
20-HETE with HET0016 exacerbated renal dysfunction
following I/R injury whereas treatment of rats with two
analogues of 20-HETE mitigated renal dysfunction and
tubular injury compared to control or HET0016-treated rats.
Although the mechanism of action remains to be determined,
this study indicates that the 20-HETE analogue, 5,14-20-
HEDGE, promotes sodium excretion in the absence of
changes in MAP, RBF, or GFR and it prevents the
postischemic fall in MBF. Taken together, the present findings
suggest that 20-HETE analogues may mitigate renal ischemia
by inhibition of renal tubular sodium transport and by
preserving postischemic MBF. Notably, 5,14-20-HEDGE was
more efficacious than 5,14-20-HEDE even though it was
administered at a 10-fold lower dose. The increased efficacy
of 5,14-20-HEDGE might be related to the addition of the
glycine group that may help the compound enter cells or
prolong its action by protecting it from b-oxidation.
Previous studies have demonstrated a pathologic function
for 20-HETE and CYP o-hydroxylase in ischemic injury to
the heart and brain. In this regard, selective inhibition of CYP
o-hydroxylase protects myocardium from ischemic injury
and inhibition of 20-HETE production counteracts cerebral
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Figure 3 | Renal histology 24 h after renal I/R injury. (a)
Hematoxylin and eosin (H&E)-stained sections demonstrating
intact (**) and necrotic (*) tubular epithelium following I/R injury.
(b) Fluorescence microscopy of the same H&E-stained field. The
necrotic tubules (*) exhibit marked autofluorescence compared to
the intact tubule (**). Original magnification,  400. (c)
Fluorescence microscopy of representative H&E-stained cross-
sections of the outer medulla is presented. Necrotic tubules
(arrowheads) exhibit marked autofluorescence compared to intact
tubules (arrows). Original magnification,  100. (d) Tubular injury
scores 24 h after renal I/R injury. Administration of the 20-HETE
analogues, 5,14-20-HEDE or 5,14-20-HEDGE, resulted in less severe
renal injury compared to vehicle controls or rats treated with
HET0016. Mean values±s.e. are presented. *Po 0.05 vs vehicle-
treated group. wPo 0.05 vs HET0016.
N
uc
le
i p
er
 H
PF
 (%
)
20
15
10
5
0
Vehicle
(n=6)
5,14-20-HEDGE
(n=5)
Figure 4 | Effect of the 20-HETE analogue, 5,14-20-HEDGE, on
apoptosis 24 h after renal I/R injury. Apoptosis of renal tubular
epithelial cells was assessed by TUNEL staining. (a) Vehicle
treated. (b) 20-HETE analogue treated. (c) The number of
apoptotic nuclei was significantly less in rats treated with the
20-HETE analogue, 5,14-20-HEDGE, when compared to vehicle-
treated controls. Mean values±s.e. are presented. *Po0.05 vs
vehicle-treated group.
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vasospasm and reduces infarct size in animal models of
ischemic stroke.10–13 On the other hand, the function of CYP-
AA metabolites and 20-HETE in acute kidney injury has not
been well characterized. Prior studies in the rat have
shown that I/R results in a decrease in renal CYP4A2
o-hydroxylase expression and microsomal conversion of
AA to 20-HETE.16,17 This was suggested to be an adaptive
response that might attenuate postischemic vasoconstriction as
20-HETE potentiates vasoconstriction of preglomerular
vessels.17 However, these studies did not associate the
reductions in CYP o-hydroxylase activity with the severity
of renal dysfunction or injury following ischemia. On the
other hand, Portilla et al.18 demonstrated that pretreatment
of rats with clofibrate to induce CYP4A expression and renal
20-HETE production, reduced renal dysfunction following
I/R injury. These findings were the first to suggest a protective
function of 20-HETE in renal I/R injury. However, clofibrate
is also an activator of peroxisome proliferator-activated
receptor-a that may afford protection from I/R by inhibiting
neutrophil infiltration, cytokine production, and oxidative
stress within the injured kidney.19 The present results are
consistent with the findings of Portilla et al. and support a
distinct protective function for 20-HETE in renal I/R and
suggest that the decrease in renal CYP o-hydroxylase activity
and 20-HETE production following ischemia is maladaptive
and contributes to renal injury and dysfunction.
The protective effect of 20-HETE analogues may
result from more than one mechanism as administration of
5,14-20-HEDGE mitigated renal I/R when given before, or
after, the ischemic interval. 20-HETE modulates vascular
responsiveness to vasoconstrictors and administration of a
20-HETE analogue would be expected to reduce RBF and
have a detrimental effect on renal I/R injury. However, the
effects of 20-HETE may differ in the cortical and medullary
circulation. In this regard, 20-HETE has been shown to
increase renal MBF in a dose-dependent manner in rats.20
Furthermore, 20-HETE had a greater effect on medullary
vasodilation than on cortical vasoconstriction.20 Several
studies have established the importance of impaired MBF
in the pathogenesis of renal I/R injury in the rat. For
example, Vetterlein et al.7 utilized fluorescent tracers to assess
postischemic blood flow and demonstrated a marked
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Figure 5 | Effect of the 20-HETE analogue, 5,14-20-HEDGE, on
renal hemodynamics after renal I/R injury. (a) The effect of
5,14-20-HEDGE (1 mg/kg s.c.) on cortical blood flow (CBF) in rats
during and following renal I/R injury. (b) The effect of 5,14-20-
HEDGE (1 mg/kg s.c.) on medullary blood flow (MBF) in rats during
and following renal I/R injury. (c) The effect of 5,14-20-HEDGE
(1 mg/kg s.c.) on mean arterial pressure (MAP) in rats during and
following renal I/R injury. Values are represented as mean±s.e.
*Po0.05 vs the corresponding value in the vehicle-treated group.
wPo0.001 vs the corresponding value in the vehicle-treated
group.
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Figure 6 | Effect of the 20-HETE analogue, 5,14-20-HEDGE, on
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reduction in medullary plasma flow 1 h after of reperfusion.
The present findings are consistent with prior studies that
utilized LDF to assess postischemic MBF. Olof et al.21 found
that MBF markedly decreased following 60 min of renal
ischemia. Conesa et al.22 also demonstrated a decrease in
MBF after renal ischemia. Furthermore, they demonstrated
that N-acetyl-L-cysteine improved MBF after reperfusion and
this directly correlated with preservation of renal function.22
In this context, we speculate that preservation of post-
ischemic MBF is at least partially responsible for the protective
effect of 20-HETE analogues demonstrated in this study.
Prevention of renal medullary hypoxia by inhibition of
tubular sodium transport might also contribute to the
renoprotective effect of 20-HETE analogues in I/R injury.
In this study, administration of 5,14-20-HEDGE to rats
resulted in a significant increase in urine sodium excretion
without changing GFR or MAP, suggesting that it inhibits
tubular reabsorption of sodium. These data are consistent
with published reports demonstrating that inhibitors of
20-HETE synthesis blunt pressure natriuresis and promote
sodium retention.23 Furthermore, 20-HETE has been shown
to inhibit Naþ -Kþ -ATPase and sodium transport in both
the proximal tubule and medullary thick ascending loop of
Henle.20,24,25 Thus, it is possible that 20-HETE analogues
attenuate medullary hypoxia by decreasing oxygen demand
during the ischemic period, thereby ameliorating renal
dysfunction in a manner similar to other inhibitors of
tubular electrolyte transport.26 For example, the selective
dopamine receptor-1 agonist Fenoldopam increases sodium
excretion similar to 20-HETE, but in contrast, is vasodilatory,
decreasing systemic blood pressure while increasing RBF.27
Fenoldopam has been clinically tested for the prevention or
treatment of acute kidney injury but the results have been
inconclusive.28
This study did not explore and cannot exclude other
mechanisms that may contribute to the renal protective
actions of 20-HETE analogues in renal I/R injury. Admin-
istration of a 20-HETE analogue might be expected to
mitigate inflammation following I/R as 20-HETE was
recently shown to activate proliferator-activated receptor-
a.29 Other pleiotropic actions of 20-HETE may include
modulation of the inflammatory response to I/R by blocking
platelet and neutrophil aggregation within the injured kidney
as well mediating vasoprotection by stimulating mitogenesis
and angiogenesis.9,30
CONCLUSION
In contrast to previous findings in the heart and brain, the
results of this study indicate that 20-HETE may exert
protective effects in the kidney following I/R injury. The
protection afforded by 20-HETE analogues in renal I/R injury
may be due to preservation of renal medullary oxygen supply
by inhibition of tubular sodium reabsorption and prevention
of the postischemic fall in MBF. Our finding that the
20-HETE analogue, 5,14-20-HEDGE, mitigated renal I/R
injury when administered after the ischemic period greatly
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increases the clinical relevance of this study. Overall, these
findings provide a basis for the development of 20-HETE
analogues as novel preventative or therapeutic agents in
ischemic acute kidney injury.
MATERIALS AND METHODS
General
Experiments were performed on 62 male Sprague–Dawley (SD) rats
weighing 250–300 g that were purchased from Taconic Farms
(Germantown, NY, USA). The rats were housed in an Animal Care
Facility at the Medical College of Wisconsin, which is approved by the
American Association for the Accreditation of Laboratory Animal
Care. All protocols were approved by the Institutional Animal Care
and Use Committee of the Medical College of Wisconsin.
20-HETE analogues
The chemical structures of the 20-HETE analogues used in this
study are shown in Figure 1. These analogues have improved
stability in vitro compared to endogenous 20-HETE. The glycine
substitution renders 5,14-20-HEDGE less susceptible to b-oxidation
and the absence of the double bonds across the 8,9- and 11,12-
carbons prevents its degradation by cyclooxygenase.31
Measurement of plasma levels of the 20-HETE analogues
Initial experiments were performed to assess the pharmacokinetics
of the 20-HETE analogues. In these experiments, a chronic polyvinyl
catheter was implanted into the jugular vein and exteriorized at the
back of the neck of SD rats several days before the experiment. After
a 3-day recovery period, the rats (n¼ 4 in each group) received an
s.c. injection of either 5,14-20-HEDE (10 mg/kg) or 5,14-20-
HEDGE (10 mg/kg) and blood samples were collected 1, 4, 8, and
24 h after administration. Plasma levels of 5,14-20-HEDE and 5,14-
20-HEDGE were measured by liquid chromatography–mass spectro-
metry using an Applied Biosystems API 3000 LC/MS/MS (Foster
City, CA, USA).
Renal ischemia-reperfusion injury model
This set of experiments was performed on six groups of rats. Group
1 underwent bilateral nephrectomy and served as an absolute renal
failure control group. Rats in the following groups were pretreated
with an s.c. injection of vehicle or one of three treatments, 30 min
before induction of renal ischemia: group 2 received 1 ml/kg of the
vehicle used for all experiments (11% sulfobutyl-b-cyclodextrin in
165 mM mannitol solution); group 3 received HET0016 (5 mg/kg), a
selective inhibitor of the formation of 20-HETE;23 group 4 received
the 20-HETE analogue, 5,14-20-HEDE (10 mg/kg); group 5
(5,14-20-HEDGE group A) received the 20-HETE analogue, 5,14-
20-HEDGE (1 mg/kg).15,31 Group 6 (5,14-20-HEDGE group B)
received 5,14-20-HEDGE (1 mg/kg, s.c.) 1 min after reperfusion.
The rats were anesthetized with ketamine (50 mg/kg, i.m.) and
sodium pentobarbital (50 mg/kg, i.p) and were placed on a heated
surgical table to maintain body temperature at 37 1C. A midline
abdominal incision was made to expose the kidneys and the renal
arteries and veins were bilaterally occluded for 30 min using
microvascular clamps. The clamps were then removed, the
abdominal incision was closed and the rats were allowed to recover
for 24 h. Rats were then killed with sodium pentobarbital (100 mg/
kg, i.p.), blood was collected from the aorta for measurement of
plasma creatinine concentration using the Jaffe reaction and both
kidneys were collected for histological analysis.
Analysis of the degree of tubular injury
The kidneys were fixed in 10% formalin and paraffin sections (3mm)
were prepared and stained with H&E. Eosin autofluorescence is
intensified in necrotic tissue.32 The sections were examined using an
Olympus BHT-2 (Olympus, Center Valley, PA, USA) epifluorescent
microscope equipped with a 540-nm excitation filter and a 590-nm
emission filter. For each specimen, five randomly chosen outer
medullary fields were photographed using a digital color camera
( 100 total magnification) and following background thresholding,
the percentage of the area containing fluorescent necrotic tubular
epithelium or cast material was quantified using Image-Pro Plus image
analysis software (version 6.2; Media Cybernetics Inc., Bethesda, MD,
USA). The severity of tubular injury (acute tubular necrosis score) for
each specimen was expressed as the mean area containing autofluor-
escent necrotic tubular epithelium or cast material. TUNEL labeling
was also performed to assess the degree of apoptosis following renal
I/R injury (ApopTag Plus In Situ Apoptosis Fluorescein Detection Kit;
Chemicon International, Temecula, CA, USA), following the manu-
facturer’s protocol. Apoptotic nuclei were visualized at  10 by
fluorescence microscopy and quantified by Metamorph analysis
(Metamorph Imaging Series Software; Molecular Devices Corporation,
Dowington, PA, USA). A total of five fields were analyzed per section,
with one section analyzed per animal. Data were expressed as the
percentage of TUNEL-positive nuclei per total number of 406-
diamidino-2-phenyl indole-stained cells.
Assessment of renal hemodynamics
These experiments were performed to determine if the renal-
protective effect of the 20-HETE analogue, 5,14-20-HEDGE, on I/R
injury was associated with changes in renal medullary hemo-
dynamics. Rats were anesthetized with ketamine (50 mg/kg, i.m.)
and inactin (100 mg/kg, i.p.; Sigma, St. Louis, MO, USA). Catheters
were placed in the femoral artery for continuous measurement of
arterial pressure and in the femoral vein for i.v. infusions. The left
kidney was then exposed and placed in a kidney holder and a single-
mode optical fiber was implanted 4 mm into the kidney for
measurement of MBF by laser-Doppler flowmetry as previously
described.33 CBF was measured by a second laser-Doppler probe
held in static position by a micromanipulator 1 mm above the renal
cortex. After surgery and a 30 min stabilization period MAP, CBF,
and MBF were continuously recorded using WinDaq data acquisi-
tion software (DATAQ Instruments Inc., Akron, OH, USA) during a
5 min control period. Baseline MAP, MBF, and CBF were
determined and then 5,14-20-HEDGE (1 mg/kg, s.c.) or vehicle
(1 ml/kg, s.c.) were administered. At 30 min later the blood supply
to the left kidney was occluded for 45 min. MAP, MBF, and CBF
were recorded during ischemia and for 3 h following reperfusion.
Additional experiments were performed in nonischemic rats to
determine the effect of 5,14-20-HEDGE on MAP, RBF, GFR, and
urinary sodium and potassium excretion. Rats were anesthetized
with ketamine (50 mg/kg, i.m.) and inactin (100 mg/kg, i.p.) and
placed on a heated table to maintain body temperature at 37 1C.
Catheters were placed in the femoral artery for continuous
measurement arterial pressure and in the femoral vein for i.v.
infusions. The left kidney was then exposed and a catheter was
placed in the left ureter for collection of urine. A 2.0-mm diameter
flow probe was placed around the left renal artery for measurement
of RBF using a small animal blood flowmeter (Transonic System,
Ithaca, NY, USA). Rats received an i.v. infusion of 0.9% NaCl
solution containing 1% bovine serum albumin and 2% FITC-Inulin
(Sigma) at 100ml/min throughout the experiment. After surgery and
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a 30 min stabilization period, urine and plasma samples were
collected during a 40 min control period. 5,14-20-HEDGE (1 mg/kg,
i.v.) was then infused over 30 min. After a 30 min equilibration
period, urine and plasma samples were recollected over a 40 min
period. MAP and RBF were continuously recorded using WinDaq
data acquisition software. GFR was determined by the clearance of
FITC-Inulin.34
Statistical analysis
Mean values±s.e. are presented. The significance of differences in
mean values between groups was analyzed using a one-way analysis
of variance, repeated measures analysis of variance with Dunns post
hoc test, or paired t-test. A P-value o0.05 was considered to be
statistically significant.
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